Skip to main content

Could 23andMe’s new pharmaceutical friends finally find a fix for psoriasis?

23andMe
Eric Baradat/Getty Images / 23andMe

In the postindustrial world, human populations are more dispersed than ever, but one of the effects of migration is that the great rifts of time and geography can leave people feeling disconnected from their ancestors. It’s no surprise then that so many people have submitted samples of their genetics to services like 23andMe, which collect these samples and evaluate them, offering insights into health and even the geographic regions their ancestors came from. Tens of millions have people have used these services, but the market for them seems to have cooled off.

If the demand for home genetic tests doesn’t bounce back, 23andMe may have a different path forward. The company has built a Therapeutics team, and since 2015 this team has used the genetic data provided by consenting customers — the company claims 80 percent of consent to the research — to develop drugs for treating specific health issues. The company has partnered with Spanish pharmaceutical company Almirall to develop an antibody that could help deal with some particularly nasty diseases.

Collaboration is humanity’s superpower. It has enabled some of the most significant advances the world has ever seen, and in this series, we’ll showcase some of the most incredible and inspiring examples of collaboration happening right now.
Event Horizon Telescope

What is IL-36? What health problems can it cause

The antibody in question is designed “to block all three members of the IL-36 cytokine subfamily … a part of the IL-1 cytokine family, which is associated with multiple inflammatory diseases.” If that sounds overly science-y and ominous, here’s a breakdown what exactly those terms mean.

Cytokines are proteins that cells secrete, and they affect communication between cells, for a variety of purposes. Interleukin-36 (IL-36) is a particular group of cytokines, but what exactly do they do?

23andMe has engineered an antibody that it says can block IL-36 cytokines.

“The highest IL-36 activities probably are found at barrier sites of an organism (skin, lungs, and intestines),” according to a review published in Frontiers in Immunology. “This indicates the importance of IL-36 cytokines in terms of protecting the body from the environment at its interfaces … The recognition of [these cytokines ] leads to the activation of pro-inflammatory pathways resulting in a higher anti-microbial activity of corresponding cells.”

Instigators of inflammation

Il-36 cytokines help cause inflammation, the red, swollen condition you might experience when you have an infection. Although irritating, inflammation does serve an important purpose as the body’s response to injuries or infection by things like bacteria. That redness and hot feeling you feel is the result of increased blood flow to the affected spot, as your body pumps more cells in to deal with the situation. Even the pain of inflammation serves a purpose, since “If the inflammation hurts, you tend to protect the affected part of the body,” according to the Institute for Quality and Efficiency in Health Care.

How Psoriasis works

As important as it is, inflammation can be a problem, particularly when it is chronic, or when the immune system is firing off without need. This can lead to health problems, and with IL-36 cytokines in particular, such problems can manifest as skin conditions like psoriasis, a skin condition that causes patches of scaly skin. As Harvard Medical School explains, psoriasis occurs when “White blood cells called T-helper lymphocytes become overactive, producing excess amounts of cytokines, such as tumor necrosis factor, interleukin-2, and interferon-gamma. In turn, these chemicals trigger inflammation in the skin and other organs.”

How does an antibody help?

Given the role cytokines can play in skin conditions, neutralizing them can help alleviate such diseases, and that’s what 23andMe’s antibody is meant to do. Antibodies are the proteins that the immune system uses to thwart bacteria and viruses by interfering with crucial mechanisms of those agents. Antibodies can also interfere with cytokines, blocking them from inciting inflammation.

Using its customer’s genetic data, 23andMe has engineered an antibody that it says can block IL-36 cytokines, and by teaming up with a dermatology-focused pharmaceutical company like Almirall, it’s possible this could help psoriasis sufferers worldwide.

Will Nicol
Former Digital Trends Contributor
Will Nicol is a Senior Writer at Digital Trends. He covers a variety of subjects, particularly emerging technologies, movies…
Rivian offers $3,000 off select EVs to gasoline, hybrid vehicle drivers
Second-Gen Rivian R1S on a road

Early November typically kicks off the run-up to the Black Friday sales season, and this year, Rivian is betting it’s the perfect time to lure gasoline drivers toward its EVs.
If you own or lease a vehicle that runs on gasoline, which means even a hybrid vehicle, Rivian is ready to give you $3,000 off the purchase of one of its select fully electric vehicles -- no trade-in required.
The offer from the Irvine, California-based automaker extends to customers in the U.S. and Canada and runs through November 30, 2024. The program applies to Rivian 2025 R1S or R1T Dual Large, Dual Max, or Tri Max models purchased from R1 Shop.
Rivian’s new All-Electric Upgrade offer marks a change from a previous trade-in program that ran between April and June. There, owners of select 2018 gas-powered vehicles from Ford, Toyota, Jeep, Audi, and BMW could trade in their vehicle and receive up to $5,000 toward the purchase of a new Rivian.
This time, buyers of the R1S or R1T Rivian just need to provide proof of ownership or lease of a gas-powered or hybrid vehicle to receive the discount when they place their order.
Rivian is not going to be the only car maker offering discounts in November. Sluggish car sales from giants such as Stellantis and rising inventories of new cars due to improving supply chains suggest automakers and dealerships will be competing to offer big incentives through the year's end.
This follows several years of constrained supply following the COVID pandemic, which led to higher prices in North America.
According to CarEdge Insights, average selling prices for cars remain above what would be called affordable. But prices should continue improving along with rising inventories.
Stellantis brands are entering November with the most inventory, followed by GM and Ford, according to CarEdge. Toyota and Honda, meanwhile, have the least inventory, meaning they probably won’t be under pressure to offer big incentives.

Read more
AT&T, Voltpost bring internet connectivity to EV charging lampposts
att voltpost streetlight charging newlabdetroit 63

Move over, Supercharger network.

EV charging networks have been fast expanding across U.S. roads and highways over the past year, led by the likes of Electrify America, Tesla, and Chargescape, to name a few.

Read more
Volvo’s much-anticipated EX30 EV to reach U.S. before year end
Front three quarter view of the 2025 Volvo EX30.

Volvo is switching gears again, this time to accelerate deliveries of its much-anticipated EX30 subcompact electric SUV so that it reaches the U.S. before the end of 2024.

The Swedish automaker last summer had postponed the U.S. launch of the EX30 to 2025, citing “changes in the global automotive landscape." The move followed the Biden administration’s 100% import tariff on electric vehicles made in China.

Read more